Prelude Capital Management, LLC Bio Atla, Inc. Transaction History

Prelude Capital Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.7 - $3.07 $8,358 - $15,095	-4,917 Reduced 30.73%	11,083 $18,000
Q2 2023 Aug 14, 2023	BUY	$2.83 - $3.87 $8,925 - $12,205	3,154 Added 24.55%	16,000 $48,000
Q1 2023 May 15, 2023	SELL	$2.3 - $8.25 $7,652 - $27,447	-3,327 Reduced 20.57%	12,846 $34,000
Q4 2022 Feb 14, 2023	BUY	$7.63 - $11.01 $123,399 - $178,064	16,173 New	16,173 $133,000
Q2 2022 Aug 15, 2022	BUY	$2.13 - $5.38 $33,696 - $85,111	15,820 New	15,820 $45,000

24.8M

140K

4.6K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $49.7M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.